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Abstract Protein phosphatase (PP) type 2A is a multi-
functional serine/threonine phosphatase that is involved in
cardiac excitation–contraction coupling. The PP2A core
enzyme is a dimer, consisting of a catalytic C and a scaf-
folding A subunit, which is targeted to several cardiac
proteins by a regulatory B subunit. At present, it is con-
troversial whether PP2A and its subunits play a critical role
in end-stage human heart failure. Here we report that the
application of purified PP2AC significantly increased the
Ca2?-sensitivity (DpCa50 = 0.05 ± 0.01) of the contractile
apparatus in isolated skinned myocytes of non-failing (NF)
hearts. A higher phosphorylation of troponin I (cTnI) was
found at protein kinase A sites (Ser23/24) in NF compared
to failing myocardium. The basal Ca2?-responsiveness of
myofilaments was enhanced in myocytes of ischemic
(ICM, DpCa50 = 0.10 ± 0.03) and dilated (DCM,
DpCa50 = 0.06 ± 0.04) cardiomyopathy compared to NF.
However, in contrast to NF myocytes the treatment with
PP2AC did not shift force-pCa relationships in failing
myocytes. The higher basal Ca2?-sensitivity in failing
myocytes coincided with a reduced protein expression of
PP2AC in left ventricular tissue from patients suffering
from ICM and DCM (by 50 and 56% compared to NF,
respectively). However, PP2A activity was unchanged in
failing hearts despite an increase of both total PP and PP1
activity. The expression of PP2AB56a was also decreased
by 51 and 62% in ICM and DCM compared to NF,
respectively. The phosphorylation of cTnI at Ser23/24 was
reduced by 66 and 49% in ICM and DCM compared to NF
hearts, respectively. Our results demonstrate that PP2A
increases myofilament Ca2?-sensitivity in NF human
hearts, most likely via cTnI dephosphorylation. This effect
is not present in failing hearts, probably due to the lower
baseline cTnI phosphorylation in failing compared to non-
failing hearts.
Keywords Protein phosphatase 2A  Myofilament
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Introduction
The balance between protein kinases and opposing phos-
phatases is crucial for normal cell function in all tissues.
Disruption of this balance between protein phosphorylation
and dephosphorylation can trigger dysfunction and disease.
Protein phosphatases are emerging as significant regulators
in cellular signaling pathways. Protein phosphatase 2A
(PP2A) has been identified as one important modulator of
cellular processes, including regulation of ion channels and
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transporters, apoptosis, transcription, development, inter-
cellular communication, and excitation–contraction cou-
pling (Herzig and Neumann 2000; Janssens and Goris
2001).
This serine/threonine phosphatase consists of a hetero-
trimer that includes a dimeric core enzyme, containing a
catalytic C subunit and a structural/scaffolding A subunit
(Shi 2009). The core enzyme is bound to a variety of
exchangeable regulatory B subunits, governing substrate
specificity, subcellular targeting, and enzymatic activity
(McCright et al. 1996; Price and Mumby 2000). One of the
four unrelated gene families of the B subunit is B0 (or B56).
Its members are encoded by five distinct genes, generating
a variety of splicing isoforms, and are preferentially
expressed in cardiac muscle (Ito et al. 2003; Zhou et al.
2007). Although there is growing knowledge about the
structural properties of PP2A subunits, there is little
information on their distribution and functional interplay in
normal and diseased myocardium.
In the heart, PP2A is associated with the b-adrenergic
receptor, connexin43, Na?/Ca2? exchanger, L-type Ca2?
channel, ryanodine receptor (RyR), phospholamban (PLB),
troponin I (cTnI), and myosin light chain 2 (MLC-2),
representing critical molecules in cellular excitability and
myocardial contractility (Ai and Pogwizd 2005; Chen et al.
2003; Deshmukh et al. 2007; Hall et al. 2006; Macdougall
et al. 1991; Marx et al. 2000; Schulze et al. 2003). In intact
myocytes localization of the PP2A regulatory B subunit
at the sarcomeres is altered by activation of e.g. the
b-adrenergic receptor (Deshmukh et al. 2007; Yin et al.
2010). The importance of PP2A targeting was tested in
transgenic mice expressing a dominant negative mutant of
the A subunit, which cannot bind regulatory B subunits,
resulting in an altered sub-cellular localization of the
enzyme, dilated cardiomyopathy, and depressed contrac-
tility (Brewis et al. 2000). The crucial role of PP2A in
regulating cardiac Ca2? signaling has been further dem-
onstrated by application of the purified enzyme to isolated
rat myocytes which was accompanied by a reduction of
cytosolic Ca2? transients (duBell et al. 1996). This is in
line with data from a transgenic mouse model with heart-
directed overexpression of PP2ACa showing a lower
phosphorylation state of PLB and cTnI, hypertrophy, and
impaired contractile function (Gergs et al. 2004). In the
latter study (Gergs et al. 2004) increased diastolic Ca2?
levels were observed in cardiomyocytes from the PP2A-
overexpressing transgenic mice, which may be due to the
reduced phosphorylation of PLB and coincident reduced
reuptake of Ca2? into the sarcoplasmic reticulum (SR) via
the SR Ca2?-ATPase. In contrast, application of PP2A
inhibitors like cantharidin and calyculin A was associated
with an increased phosphorylation of PLB, higher L-type
Ca2? currents and Ca2? transients, and enhanced force of
contraction (Boknik et al. 2001; duBell et al. 2002). These
effects were independent of an increase in intracellular
cAMP, an altered myofilament Ca2?-sensitivity, or K?
current inhibition (duBell et al. 2002; Neumann et al. 1994,
1995). Because a number of studies suggested a regulatory
role of PP2A in normal myocardium and in animal models
of the diseased heart, we hypothesized that the activity
state of the PP2A multimeric complex is important for the
progression of human heart failure.
Thus, the aim of the present study was to determine the
functional relevance of PP2A by measuring the Ca2?-
sensitivity of myofilaments in the presence and absence of
PP2AC in isolated skinned myocytes of non-failing and
failing human hearts. Moreover, we tested whether
potential effects in myofilament Ca2?-sensitivity are par-
alleled by changes in PP2A expression and activity in
failing hearts. Finally, we examined if differences in
myofilament responsiveness to PP2A and in PP expres-
sion/activity correspond with the phosphorylation status of
myofilament proteins in failing and non-failing human
myocardium.
Methods
Human myocardial tissue
Right (RV) and left ventricular (LV) tissue was obtained
from patients undergoing heart transplantation due to end-
stage heart failure resulting from ischemic (ICM) or dilated
cardiomyopathy (DCM) and from non-failing hearts (NF)
that could not be transplanted due to medical reasons or
blood group incompatibility (Table 1). Most patients
received diuretics, cardiac glycosides, ACE inhibitors, and
carvedilol (for detailed information see Table 1). Myo-
cardial tissue was quickly transferred to cold cardioplegic
solution and upon arrival in the laboratory, stored in liquid
nitrogen. Care was taken not to use scarred, fibrotic, adi-
pose samples, endocardium, epicardium, or great vessels.
Tissue was frozen within 1 h of explantation. Permissions
for the study were obtained from the local Ethic’s Com-
mittees of the University Hospital of Mu¨nster and the St
Vincents’ Hospital Human Research Ethics Committee in
Sydney, Australia (File number: H03/118; Title: Molecular
Analysis of Human Heart Failure). The investigation con-
formed with the principles outlined in the Declaration of
Helsinki.
Isolation and skinning of myocytes
Myocytes from LV of non-failing and failing hearts were
mechanically isolated on ice as described previously (van
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der Velden et al. 1998). In the ICM group myocytes were
isolated from the non-ischemic remodeled part of the left
ventricle. Briefly, tissue was thawed in isolation solution
containing 10 mmol/l imidazole (pH 7.0), 140 mmol/l
KCl, 6 mmol/l Na2ATP, 2 mmol/l EGTA, and 6 mmol/l
MgCl2. All membrane structures of isolated myocytes were
dissolved by incubation with the isolation solution sup-
plemented with 0.5% Triton X-100 for 5 min at 4C. At
this temperature the kinases and the phosphatases are
inactive and therefore during myocyte isolation and skin-
ning the phosphorylation status remains unchanged. In
addition, after skinning all the soluble and membrane-
bound protein kinases and phosphatases are washed away
by washing three times with Triton-free isolation solution.
The phosphorylation status of myofibrillar proteins is not
affected by the procedure (Duncker et al. 2009; Kooij et al.
2010a, b; van der Velden et al. 2003a). Skinned myocytes
were kept at 4C up to 24 h.
Measurement of force-[Ca2?] relation in skinned
myocytes
The use of skinned myocytes allows the study of myo-
fibrillar contractility under standardized conditions, i.e.
composition of intracellular buffer and sarcomere length.
Measurement of isometric force was performed at 15C
and sarcomere length was set to 2.2 lm (van der Velden
et al. 2003b). The composition of relaxing and activating
solutions (pH 7.1) was calculated as described (Fabiato
1981). The pCa value, i.e. -log10[Ca
2?], of the relaxing
and activating solution were set to 9.0 and 4.5, respec-
tively. Solutions with intermediate free [Ca2?] were
obtained by appropriate mixing. Measurement of isometric
force was started with a first activation of the myocyte at a
pCa value of 4.5. The second activation was used to
determine maximal isometric tension. The next measure-
ments were performed at submaximal [Ca2?], followed by
Table 1 Patient characteristics
Age Gender Diagnosis NYHA EF CI PCWP Drugs
63 M NF n.d.
44 M NF n.d.
69 M NF n.d.
23 M NF n.d.
19 M NF n.d.
n.d. n.d. NF n.d.
48 M ICM III–IV 2.5 18 D, G, N, A, C
58 M ICM IV 2.2 22 D, G, N, A
41 F ICM
51 M ICM
60 M ICM III–IV 25 2.7 30 D, G, A, R
61 M ICM 2.8 11 A, B
52 M ICM 20 1.7 18 D, G, C
43 M ICM III–IV 2.0 11 D, N, A, C
32 F ICM
47 M ICM 3.1 16
n.d. n.d. ICM n.d. n.d. n.d. n.d. n.d.
61 M DCM II–III 1.8 21 D, G, N, C, R
53 M DCM III 25 2.4 22 D, D, A, C, R
57 M DCM III–IV 10–20 2.6 17 D, G, N, A, C
49 M DCM
51 M DCM III–IV 14 2.9 29 D, G, N, A
52 M DCM II–III 2.8 11 D, G, A, C, R
43 M DCM IV 19 G, A, C
36 M DCM III 2.5 26 D, A, C
50 M DCM IV D, C
27 M DCM 3.4 4
EF (%) LV ejection fraction, CI (l/min m2) cardiac index, PCWP (mmHg) pulmocapillary wedge pressure, D diuretics, G glycosides, N nitrates,
A ACE inhibitors or angiotensin II receptor antagonists, C carvedilol, R antiarrhythmics, B b-adrenergic receptor blockers
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a final control measurement at maximal [Ca2?]
(pCa = 4.5). Force values at submaximal [Ca2?] were
normalized to interpolated control values, taking into
account a linear reduction in maximal force with each
activation. This force-[Ca2?] relationship was repeated
after treatment with exogenous PP2A. For this purpose,
myocytes were incubated for 40 min at 20C in relaxing
solution containing 5 U/ml of the active or heat-inactivated
catalytic subunit (a/b) of PP2A (Promega). At this tem-
perature PP2A is active and dephosphorylates its target
proteins. PP2A was not present in the solutions used during
the tension-pCa measurements. Incubation for 40 min at
20C in relaxing solution without PP2A did not change
phosphorylation status of the myofilament proteins
(unpublished data). Force-[Ca2?] relations were fit to a
modified Hill equation (van der Velden et al. 2003a).
The maximal rate of force redevelopment (max ktr) was
determined from an exponential curve fit of force rede-
velopment after a slack test in activating solution with
pCa 4.5.
Immunological detection of PP2A subunits
Frozen RV and LV tissue of human hearts was homoge-
nized at 4C for 90 s in a buffer containing 20 mmol/l Tris/
HCl (pH 7.4), 1 mmol/l EDTA, 5 mmol/l MgCl2, 1 mmol/l
DTT, and protease inhibitors. After incubation for 20 min
on ice samples were centrifuged at 15,800 9 g for 15 min.
Supernatants were diluted in 5% SDS buffer containing
62.5 mmol/l Tris/HCl (pH 6.8), 5% glycerol, and 40 mmol/
l DTT. For immunoblot analysis different amounts of
solubilized proteins were separated electrophoretically in
10% SDS–polyacrylamide gels. Proteins were transferred
to nitrocellulose for immunoblotting. Nitrocellulose
sheets were probed with different antibodies: polyclonal
anti-PP2ACa/b antibody (Santa Cruz Biotechnology), a
polyclonal anti-Aa antibody (Santa Cruz), a polyclonal
anti-B56a antibody (Santa Cruz), and a polyclonal anti-
calsequestrin antibody (Kirchhefer et al. 2001). Antibody
binding was visualized by alkaline phosphatase-conjugated
secondary antibodies (Amersham Biosciences) or by
125I-labeled protein A (PerkinElmer) followed by autora-
diography. Labeling intensities were quantified with use of
a PhosphorImager.
Analysis of the phosphorylation status of myofilament
proteins
LV samples were TCA(trichloroacetic acid)-treated as
described previously (Zaremba et al. 2007). Samples were
separated on a gradient gel (Criterion Tris–HCl 4–15% gel,
BioRad) and proteins were stained for 1 h with ProQ
Diamond Phosphoprotein Stain (Molecular Probes)
(Hamdani et al. 2010). Staining was visualized using the
LAS-3000 Image Reader (FUJI; 460 nm/605 nm Ex/Em;
2 min illumination) and signals were analyzed with AIDA.
Subsequently, gels were stained overnight with SYPRO
Ruby stain (Molecular Probes) and visualized with the
LAS-3000. ProQ-stained phosphorylated proteins were
normalized to SYPRO Ruby-stained myosin binding pro-
tein C (cMyBP-C) to correct for differences in sample
loading. Gel electrophoresis and Western blotting was
performed to analyze bisphosphorylation of cTnI at PKA
sites Ser23/24 (rabbit polyclonal antibody, Cell Signaling;
dilution 1:500). Signals were normalized to actin to correct
for differences in protein loading.
Incubation of myofilaments with PP2A
To assess the effect of PP2A on myofilament protein
phosphorylation, NF myocardium was isolated and skinned
as described above (as for force measurements) and incu-
bated in relaxing solution with 0.5 U or 5 U exogenous
PP2AC for 40 min at RT. In the control incubation no
PP2A was added to NF tissue. After incubation, protein
was isolated via the 2-D Clean-Up Kit (GE Healthcare) and
dissolved in 1D-sample buffer containing 15% glycerol
(v/v), 62.5 mM Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v)
DTT. To determine the phosphorylation status of the
myofilament proteins ProQ Diamond Phosphoprotein Stain
was used. The amount of phosphorylation of cTnI-Ser23/
24 was studied via Western blotting.
Protein phosphatase assay
PP activity was determined with [32P]-phosphorylase a as
substrate (Boknik et al. 2000). Portions of pulverized fro-
zen LV tissue were homogenized at 4C for 3 9 30 s each
with a Polytron in a buffer containing 4 mmol/l EDTA and
15 mmol/l b-mercaptoethanol (pH 7.4). The homogenate
was centrifuged for 20 min at 14,000 9 g. The incubation
mixture contained 20 mmol/l Tris/HCl (pH 7.0), 5 mmol/l
caffeine, 0.1 mmol/l EDTA, and 0.1% b-mercaptoethanol
(vol/vol). The reaction was started by adding aliquots of
supernatants, and 3 nmol/l okadaic acid was used to dif-
ferentiate between PP1 and PP2A activity. The reaction
was stopped by addition of 50% TCA. Precipitated protein
was sedimented by centrifugation, and the radioactivity
was counted in the supernatant.
Statistics
Data are reported as means ± SEM. Statistical differences
between groups were calculated by ANOVA followed by
Bonferroni’s t-test. P \ 0.05 was considered significant.
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Results
PP2A increases force development at submaximal
[Ca2?] in NF myofilaments
To investigate whether the dephosphorylation of contractile
proteins by PP2A directly influences isometric force devel-
opment, we applied the catalytic subunit of the enzyme to
skinned myocytes from NF hearts. For this purpose, single
myocytes were attached between a force transducer and a
piezoelectric motor (Fig. 1a). All experiments were per-
formed on the stage of an inverted microscope. In Fig. 1b
representative recordings of force development before and
after application of PP2AC at saturating (pCa = 4.5) [Ca
2?]
are shown. Treatment of myocytes with PP2AC did not
change maximal or passive isometric force (Table 2). Rep-
resentative recordings of force development at submaximal
(pCa values ranged from 5.0 to 6.0; here pCa = 5.4) [Ca2?]
are shown in Fig. 1b and demonstrate a higher force devel-
opment after PP2A treatment indicating that Ca2?-sensitiv-
ity is modulated by the enzyme in NF myocytes. Indeed, the
measurement of the force-pCa relationship (Fig. 1c)
revealed a higher Ca2?-responsiveness of the myofilaments
after incubation with PP2AC as evidenced by an enhanced
pCa50 value (DpCa50 = 0.05 ± 0.01). Incubation of skin-
ned myocytes with heat-inactivated PP2A did not shift force-
pCa relationship demonstrating an enzyme-specific effect
(data not shown).
Fig. 1 The image shows a
single NF myocyte in relaxing
solution attached between a
force transducer and a
piezoelectric motor (a). Shown
are original recordings (b) of
isometric force development in
a Triton-skinned NF myocyte
before and after treatment with
PP2AC. The force was recorded
at a sarcomere length of 2.2 lm
during maximal activation at
pCa = 4.5 and submaximal
activation at pCa = 5.4. Force
increases when the myocyte is
transferred from the relaxing
solution (pCa = 9.0) into the
activating solution. After
reaching steady state force, the
cardiomyocyte was 20%
reduced in length within 2 ms
and re-stretched after 30 ms
(slack test). During this slack
test, force first dropped to zero
and after the re-stretch quickly
redeveloped to the original
steady state level. Subsequently,
the cell was transferred back to
relaxing solution and a second
slack test was started to
determine passive force. The
active force of a myocyte is the
steady state force (maximal
force) minus the passive force.
The summarized force-pCa
relationship is given (c; 6 NF,
14 cells)
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Higher basal Ca2? sensitivity in ischemic heart failure
but no effect by PP2A
Ca2?-sensitivity was also determined before (Fig. 2a) and
after (Fig. 2b) PP2AC application in failing myocytes by
measuring force in activating solutions with submaximal
[Ca2?] obtained by appropriate mixing of the activating and
relaxation solutions. After maximal activation (pCa = 4.5)
six measurements were carried out at submaximal [Ca2?]
followed by a maximal activation. Cells were excluded
from the data when the active force dropped more than 20%
between the first and the last measurement at pCa = 4.5
before PP2AC treatment of the cells. In ICM myocyte
preparations, the basal Ca2?-sensitivity was significantly
higher compared to NF (DpCa50 = 0.10 ± 0.03) (Fig. 2c).
However, PP2AC treatment did not further shift force-pCa
relationship (DpCa50 = 0.01 ± 0.01) suggesting maximal
dephosphorylation in ICM myocytes. In DCM myocardium,
basal Ca2?-sensitivity was also higher compared to NF
(DpCa50 = 0.06 ± 0.04), however not significantly (Fig. 2c).
The application of PP2AC did not change the Ca
2?-respon-
siveness of myofilaments compared to untreated DCM
myocytes (DpCa50 = 0.01 ± 0.01).
PP2A does not effect the steepness of the force-pCa
curves and rate of tension redevelopment
The steepness of the force-pCa curves (nH) and the max-
imal rate of tension redevelopment (max ktr) were also
determined before and after PP2AC treatment. Both nH and
max ktr were not significantly affected by PP2A in NF,
ICM and DCM cardiomyocytes (Table 2).
PP2A dephosphorylates cTnI in donor cardiomyocytes
NF heart tissue was incubated with 0.5 U or 5 U PP2AC
to test which myofilament proteins were dephosphoryl-
ated by PP2A. Via SYPRO Ruby and ProQ Diamond
stainings of gels it was demonstrated that PP2A
dephosphorylates cTnI (Fig. 3a). The phosphorylation
level of other myofilament proteins (cMyBP-C, troponin
T, Desmin and MLC-2) was not affected (data not
shown). Western blotting with an antibody raised against
bis-phosphorylated cTnI at PKA sites Ser23/24 confirmed
that cTnI was dephosphorylated by PP2A at the PKA
sites (Fig. 3b).
Reduced PKA-dependent cTnI phosphorylation
in human heart failure
To study whether an altered basal phosphorylation level of
myofilament proteins is responsible for the higher basal
Ca2?-responsiveness in failing hearts, we performed SY-
PRO Ruby and ProQ Diamond stainings of gels loaded
with NF, ICM and DCM LV samples (Fig. 4a). Total
phosphorylation of cTnI was lower in failing samples
compared to NF hearts (Fig. 4b). No differences were
observed in the phosphorylation status of the other myo-
filament proteins on the gel. The phosphorylation level of
cTnI at PKA-sites was studied by Western blotting using a
phosphospecific antibody against bis-phosphorylated
Ser23/24 of cTnI (Fig. 4c). Here we measured a lower
PKA-dependent phosphorylation of cTnI in ICM and DCM
hearts compared to NF tissue.
Table 2 Overview of force measurements in NF, ICM and DCM cardiomyocytes before and after PP2A incubation
Fmax Fpas pCa50 nH Max ktr
Non-Failing (6 hearts, 14 myocytes)
Before PP2A 19.2 ± 2.5 1.8 ± 0.2 5.43 ± 0.02 5.1 ± 0.4 0.67 ± 0.06
After PP2A 19.0 ± 2.5 2.0 ± 0.2 5.48 ± 0.01** 4.9 ± 0.2 0.70 ± 0.03
ICM (6 hearts, 14 myocytes)
Before PP2A 19.3 ± 3.0 2.1 ± 0.2 5.53 ± 0.03# 4.3 ± 0.3 0.65 ± 0.06
After PP2A 19.4 ± 2.6 2.1 ± 0.1 5.54 ± 0.03 4.2 ± 0.3 0.60 ± 0.03
DCM (6 hearts, 13 myocytes)
Before PP2A 19.6 ± 2.3 3.2 ± 0.6 5.50 ± 0.03 4.4 ± 0.3 0.60 ± 0.06
After PP2A 19.4 ± 2.0 3.3 ± 0.5 5.51 ± 0.03 4.4 ± 0.1 0.67 ± 0.04
Fmax maximal force in kN/m
2, Fpas passive force in kN/m
2, pCa50 and nH midpoint and steepness of the force-pCa curves, respectively, Max ktr
rate of tension redevelopment (s-1) at saturating calcium concentration (pCa 4.5)
** P \ 0.01 before vs. after PP2A treatment (Repeated measures Two-Way ANOVA, n = 6)
# P \ 0.05 vs. NF (Two-Way ANOVA (Source of Variation: patient) NS, One-way ANOVA (Ca2? sensitivity NF, ICM, DCM before PP2A)
P = 0.06, Bonferroni’s Multiple comparison test NF vs ICM P \ 0.05, n = 6)
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Reduced expression of PP2A subunits Ca/b and B56a
in failing hearts
To test whether PP2A may be involved in the higher basal
myofilament Ca2?-sensitivity of failing human hearts, we
determined the expression level of major PP2A subunits in
heart samples from patients suffering from ischemic and
dilated cardiomyopathy. The catalytic subunit C of PP2A
was detected as a 36-kDa protein in cardiac homogenates
(Fig. 5a). In RV tissue, PP2AC protein expression was
unchanged between all groups investigated, whereas it was
reduced by 50 and 56% in LV of ICM and DCM, respec-
tively, compared to NF hearts. Moreover, we found that the
expression of B56a was decreased in RV tissue by 87% in
DCM but not in ICM hearts compared to NF (Fig. 5b). In
contrast, the expression of B56a was reduced in LV
homogenates of both ICM (by 51%) and DCM (by 62%)
hearts. All samples were also probed with an antibody
recognizing the structural subunit of PP2A, Aa. This sub-
unit runs at 65 kDa on SDS–PAGE (Fig. 5c). Here, we
measured a similar protein expression of Aa in ventricles
of ICM, DCM, and NF hearts. Linearity of signals detected
by immunoblot analysis of heart samples was confirmed
(data not shown). Signals were standardized to the
expression of calsequestrin, acting as the main SR Ca2?
storage protein. No difference in the protein expression of
calsequestrin was detected between failing and non-failing
hearts (data not shown). This is in agreement with data
from other heart failure models (Phillips et al. 1998).
Unchanged PP2A but increased PP1 activity in ICM
hearts
The measurement of PP activity was used to determine
whether the lower PP2AC expression in failing LV myo-
cardium is paralleled by comparable changes of the catalytic
activity. Total phosphatase activity was enhanced by 35% in
ICM compared to non-failing homogenates, whereas no
difference was observed between DCM and NF (Fig. 6a). To
discriminate PP2A activity from PP1 activity, we added
3 nmol/l okadaic acid (OA) to the reaction mixture, a con-
centration known to inhibit only PP2A but not PP1 (Cohen
1991). Under our experimental conditions (phosphorylase
a as substrate, absence of divalent cations) only PP1 and
PP2A is measurable. Therefore, PP2A activity was deter-
mined as total activity minus activity in the presence of
3 nmol/l OA. The contribution of PP2A to the total PP
activity was shifted from 52% in non-failing hearts to 41% in
ICM hearts. However, total PP2A activity was unchanged
between ICM and NF preparations (Fig. 6b). The higher total
phosphatase activity in ICM reflects an increase in PP1
activity. In DCM hearts, PP2A and PP1 activities were
unchanged compared to NF samples (Fig. 6b).
Do
no
r
ICM DC
M
5.4
5.5
5.6
Before PP2A
After PP2A
**
#
pC
a 5
0
(a)
(b)
(c)
Fig. 2 Isometric force was determined at different [Ca2?] before
(a) and after (b) treatment with PP2AC in NF (6 NF, 14 cells) and
failing (ICM, 6 patients, 14 cells; DCM, 6 patients, 13 cells)
myocytes. Force at submaximal [Ca2?] was normalized to the force
at saturating [Ca2?] (pCa = 4.5). PP2AC treatment increased
Ca2?-sensitivity only in NF cardiomyocytes (c). Basal Ca2?-sensi-
tivity was higher in ICM compared to NF. **P \ 0.01 before vs. after
PP2A treatment (Repeated measures Two-Way ANOVA, n = 6);
#P \ 0.05 vs. NF (Two-Way ANOVA (Source of Variation: patient)
NS, One-way ANOVA (Ca2?-sensitivity NF, ICM, DCM before
PP2A) P = 0.06, Bonferroni’s Multiple comparison test NF vs ICM
P \ 0.05, n = 6)
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Discussion
In the present study, we tested whether PP2A is involved in
the regulation of myofilament contractility in human Tri-
ton-permeabilized cardiomyocytes. The application of
PP2AC resulted in a higher Ca
2?-sensitivity and dephos-
phorylation (at PKA sites) of cTnI in non-failing LV
myocardium indicating that PP2A may modulate myofila-
ment function by dephosphorylation of cTnI. PP2AC
treatment of non-failing myocytes changed the cTnI
phosphorylation level as well as the myofilament
Ca2?-sensitivity to a level intermediate between the base-
line levels observed in non-failing myocytes and failing
myocytes. This finding is in line with studies showing cTnI
as a main target of PP2A (Deshmukh et al. 2007; Yin et al.
2010). Our data are in contrast to control myocytes of
whole rat hearts where the addition of PP2AC had no effect
on myofilament Ca2?-sensitivity (Belin et al. 2007). This
suggests that PP2A is more effective in human than in
rodent myocardium. It is conceivable that differences in the
developmental regulation are responsible for the functional
differences between both species. For example, mRNA
expression, protein levels, and activity of PP2A were lower
in adult compared to embryonic rat hearts suggesting a
limited role of the enzyme in regulating myofilament
contractility in rat heart (Gombosova et al. 1998; Heller
et al. 1998).
Next we measured the basal Ca2?-sensitivity of force in
failing myocytes. The higher Ca2?-responsiveness in fail-
ing compared to NF myocytes is in accordance with pre-
vious studies on failing human hearts (van der Velden et al.
2003a; van der Velden et al. 2003b; Wolff et al. 1996). A
higher Ca2?-sensitivity in failing hearts has been ascribed
to a reduction in the PKA-mediated phosphorylation of
cardiac myofilament proteins (Wolff et al. 1996). Indeed,
we detected a diminished PKA-dependent cTnI phosphor-
ylation in failing myocardium. This may be caused by a
depressed b-adrenergic signaling characterized by a
decreased b-adrenergic receptor density, a higher Gi
expression, and reduced cAMP levels (Feldman 1993).
Consistent with this, the application of PKA abolished the
increased Ca2?-sensitivity of force in failing human myo-
cytes leading to values observed in non-failing cells in the
absence of the enzyme (van der Velden et al. 2003b). In the
latter study a positive correlation between Ca2?-sensitivity
and dephosphorylated cTnI was observed. On the other
hand, Ca2?-sensitivity is not only dependent on kinase
(PKA)-mediated phosphorylation of myofilament proteins
but also on the dephosphorylation by PP’s. In the present
study, we found an unchanged PP2A and a higher PP1
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activity in failing hearts. Incubation of non-failing
human myocytes with PP1 has been associated with a
reduced Ca2?-sensitivity of force and hastened relaxation.
These effects were explained by a dephosphorylation of
MLC-2 (van der Velden et al. 2003a). It is conceivable
that the desensitization by a PP1-dependent MLC-2
dephosphorylation was overcome by the effect of cTnI
dephosphorylation resulting in an overall higher basal
Ca2?-responsiveness of force in failing samples. In
contrast to non-failing myocytes, PP2AC administration
had no effect on Ca2?-sensitivity in failing myocytes. In
agreement with our data, the addition of purified PP2AC
had no effects on Ca2? sensitivity in a rat model of con-
gestive heart failure (Belin et al. 2007). PP2A-dependent
dephosphorylation of native thin filaments isolated from
human ICM and DCM ventricles was also associated with
an unchanged Ca2?-sensitivity (Noguchi et al. 2004).
These data suggest that PP2A does not exert a functional
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effect in failing hearts due to the low cTnI phosphorylation
level.
The functional effects of exogenously applied PP2AC on
Ca2?-sensitivity of force may also depend on the expres-
sion of the enzyme and its subunits. Here, the reduced
PP2AC expression in failing LV may have significant
consequences for myofilament contraction since Ca was
identified as the predominant isoform in human myocar-
dium (Luss et al. 2000). In animal models, an increased
PP2A activity was measured in rat hearts after long-term
b-adrenergic stimulation, resulting in a compensated
hypertrophy (Boknik et al. 2000). A higher PP2A expres-
sion and activity was also detected in hearts of mice with
primary pulmonary hypertension (Larsen et al. 2008). In a
dog model of acute myocardial infarction, PP2A expres-
sion was also enhanced 5 days post occlusion in the border
zone (Hund et al. 2009). In contrast, Gupta and co-workers
(2003) failed to detect any differences of PP2A activity in
microembolized dog hearts, resulting in chronic heart
failure. Therefore, it was surprising that the PP2AC
expression was reduced in failing human hearts. It appears
that an acute myocardial stress by either mechanical
overload (e.g. induced by b-adrenergic stimulation) or
phases of ischemia is associated with an increase of the
catalytic subunit, whereas in decompensated heart failure
PP2AC expression is decreased. It is also conceivable that
the lower PP2AC expression may compensate for the
reduced PKA-dependent phosphorylation of cTnI or the
enhanced PP1 activity in ICM heart homogenates. A higher
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PP1 activity was also observed in SR membrane prepara-
tions of failing human DCM hearts, whereas no significant
difference between PP activities in homogenates was noted
(Neumann et al. 1997), as observed in the present study.
The detrimental effects of an increased PP1 activity to
cardiac contractility were demonstrated in transgenic mice
(Carr et al. 2002). Beyond this simplified model of keeping
a cellular homeostasis between the main cardiac PP iso-
forms, the lower expression of PP2AC in ICM might help
to protect the heart tissue against ischemic damages. In this
context, fostriecin, an inhibitor of PP2A, limited myocar-
dial infarct size in isolated rabbit hearts when administered
after the onset of ischemia (Weinbrenner et al. 1998),
whereas transgenic mice with cardiac-specific overexpres-
sion of PP2ACa exhibited isles of necrosis, fibrosis, and
contractile failure (Gergs et al. 2004).
Interestingly, PP2AC expression was decreased in LV but
not in RV chambers of failing hearts. Data on protein
expression comparing different chambers of failing hearts
are rare. It has been shown that the expression levels of
PP2A-associated connexin43 (Ai and Pogwizd 2005;
Dupont et al. 2001) and L-type Ca2? channel (Gruver et al.
1994) are reduced in LV of failing human hearts, indicating a
predominant affection of the LV function in heart failure. It
remains to be tested whether the lower expression of PP2AC
compensates for the reduction of both regulatory proteins in
failing LV. Alternatively, the inhibition of PP2AC has been
shown to minimize the metabolic damage of LV tissue in
failing myocardium (Weinbrenner et al. 1998).
In the present study, the lower PP2AC expression was
not followed by a corresponding change in activity. This
discrepancy may depend on the subcellular distribution of
the enzyme which can be modulated by the expression of
its regulatory subunits (e.g. B56a). In failing human hearts,
we have demonstrated a concomitantly reduced expression
of PP2AB56a. As reported above, B56a is thought to be
responsible for the subcellular targeting of the PP2A
dimeric core enzyme to specific substrates (Depaoliroach
et al. 1994). A marked loss in B56a protein expression was
also detected in rat neonatal myocytes after activation of
JNK, a stress-related stimulus in the manifestation of car-
diac hypertrophy and failure (Glaser et al. 2006). A
decrease in PP2AB56a expression was also measured in a
model of sepsis-associated cardiac dysfunction (Marshall
et al. 2009). The down-regulation was associated with a
lower expression of PP2AC and increased cTnI phosphor-
ylation levels. This supports the hypothesis that a reduced
PP2AB56a expression may impair the targeting of PP2AC to
its subcellular sites. Indeed, decreased levels of RyR-bound
PP2AC were detected in failing human hearts (Marx et al.
2000). This may contribute to a hyperphosphorylation of
the channel, resulting in a defective regulation of excita-
tion–contraction coupling. Here, we detected higher
expression levels of PP2AB56a in LV compared to RV of
non-failing and failing hearts. These differences may point
to localized responses to cardiac overload. For instance,
bMHC transcript levels were lower in LV suggesting that
there is more need for an increase in contractility in LV
compared to RV (Sharma et al. 2003). Consistently, LV
exhibits a higher RyR expression (Munch et al. 2000)
which enables a stronger SR Ca2? release and high con-
tractile velocity of myofibrils. We suggest that a higher
PP2AB56a expression in LV may help to target the catalytic
subunit to the more abundant RyR.
Our data indicate that PP2A may be involved in the
regulation of the myofilament Ca2?-sensitivity in non-
failing human hearts. In contrast, PP2A had no effect on
the enhanced basal Ca2?-sensitivity in failing myocytes
which might result from the depressed PKA-dependent
basal phosphorylation of cTnI in failing hearts. The lower
expression of the catalytic subunit and B56a in ICM might
be compensatory mechanisms in order to normalize the
higher basal Ca2?-sensitivity.
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